Switch theme
Sign up to access all valuation multiples
TOWA Pharmaceutical Co Ltd is a Japan based pharmaceutical company engaged in research and development, production, and marketing of generic drugs. It also provides drug consulting services for patients and their families and relatives. It organizes academic seminars for medical professionals and posts articles in journals. It participates in training for pharmacists. The company has three main plants in operation namely Osaka plant, Okayama plant, and Yamagata plant. Towa has offers more than 500 drugs to meet the diverse therapeutic requirements including lifestyle related diseases such as hypertension and diabetes, digestive system diseases, nervous system diseases and allergic diseases, vitamins and antibiotics.
1957
3.1K+
LTM Revenue $1.8B
LTM EBITDA $294M
$2.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
TOWA Pharmaceutical has a last 12-month revenue (LTM) of $1.8B and a last 12-month EBITDA of $294M.
In the most recent fiscal year, TOWA Pharmaceutical achieved revenue of $1.6B and an EBITDA of $297M.
TOWA Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See TOWA Pharmaceutical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.8B | XXX | $1.6B | XXX | XXX | XXX |
| Gross Profit | $660M | XXX | $559M | XXX | XXX | XXX |
| Gross Margin | 37% | XXX | 36% | XXX | XXX | XXX |
| EBITDA | $294M | XXX | $297M | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 19% | XXX | XXX | XXX |
| EBIT | $163M | XXX | $121M | XXX | XXX | XXX |
| EBIT Margin | 9% | XXX | 8% | XXX | XXX | XXX |
| Net Profit | $128M | XXX | $111M | XXX | XXX | XXX |
| Net Margin | 7% | XXX | 7% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $1.2B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, TOWA Pharmaceutical's stock price is JPY 3055 (or $21).
TOWA Pharmaceutical has current market cap of JPY 150B (or $1.0B), and EV of JPY 336B (or $2.3B).
See TOWA Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.3B | $1.0B | XXX | XXX | XXX | XXX | $2.60 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, TOWA Pharmaceutical has market cap of $1.0B and EV of $2.3B.
TOWA Pharmaceutical's trades at 1.5x EV/Revenue multiple, and 8.7x EV/EBITDA.
Equity research analysts estimate TOWA Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
TOWA Pharmaceutical has a P/E ratio of 8.1x.
See valuation multiples for TOWA Pharmaceutical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.0B | XXX | $1.0B | XXX | XXX | XXX |
| EV (current) | $2.3B | XXX | $2.3B | XXX | XXX | XXX |
| EV/Revenue | 1.3x | XXX | 1.5x | XXX | XXX | XXX |
| EV/EBITDA | 7.8x | XXX | 8.7x | XXX | XXX | XXX |
| EV/EBIT | 14.1x | XXX | 23.0x | XXX | XXX | XXX |
| EV/Gross Profit | 3.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 8.1x | XXX | 11.9x | XXX | XXX | XXX |
| EV/FCF | -48.8x | XXX | -11.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTOWA Pharmaceutical's last 12 month revenue growth is 7%
TOWA Pharmaceutical's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.1M for the same period.
TOWA Pharmaceutical's rule of 40 is 25% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
TOWA Pharmaceutical's rule of X is 35% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for TOWA Pharmaceutical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Growth | 13% | XXX | 13% | XXX | XXX | XXX |
| Rule of 40 | 25% | XXX | 25% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 35% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 28% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
TOWA Pharmaceutical acquired XXX companies to date.
Last acquisition by TOWA Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . TOWA Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was TOWA Pharmaceutical founded? | TOWA Pharmaceutical was founded in 1957. |
| Where is TOWA Pharmaceutical headquartered? | TOWA Pharmaceutical is headquartered in Japan. |
| How many employees does TOWA Pharmaceutical have? | As of today, TOWA Pharmaceutical has 3.1K+ employees. |
| Is TOWA Pharmaceutical publicy listed? | Yes, TOWA Pharmaceutical is a public company listed on TKS. |
| What is the stock symbol of TOWA Pharmaceutical? | TOWA Pharmaceutical trades under 4553 ticker. |
| When did TOWA Pharmaceutical go public? | TOWA Pharmaceutical went public in 2004. |
| Who are competitors of TOWA Pharmaceutical? | Similar companies to TOWA Pharmaceutical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of TOWA Pharmaceutical? | TOWA Pharmaceutical's current market cap is $1.0B |
| What is the current revenue of TOWA Pharmaceutical? | TOWA Pharmaceutical's last 12 months revenue is $1.8B. |
| What is the current revenue growth of TOWA Pharmaceutical? | TOWA Pharmaceutical revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of TOWA Pharmaceutical? | Current revenue multiple of TOWA Pharmaceutical is 1.3x. |
| Is TOWA Pharmaceutical profitable? | Yes, TOWA Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of TOWA Pharmaceutical? | TOWA Pharmaceutical's last 12 months EBITDA is $294M. |
| What is TOWA Pharmaceutical's EBITDA margin? | TOWA Pharmaceutical's last 12 months EBITDA margin is 16%. |
| What is the current EV/EBITDA multiple of TOWA Pharmaceutical? | Current EBITDA multiple of TOWA Pharmaceutical is 7.8x. |
| What is the current FCF of TOWA Pharmaceutical? | TOWA Pharmaceutical's last 12 months FCF is -$47.2M. |
| What is TOWA Pharmaceutical's FCF margin? | TOWA Pharmaceutical's last 12 months FCF margin is -3%. |
| What is the current EV/FCF multiple of TOWA Pharmaceutical? | Current FCF multiple of TOWA Pharmaceutical is -48.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
